Mycenax Biotech Inc. (TPEX:4726)

Market Cap	5.63B -18.1%
Revenue (ttm)	815.34M +12.4%
Net Income	-436.48M
EPS	-2.11
Shares Out	207.23M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	267,803
Open	27.30
Previous Close	27.30
Day's Range	27.15 - 27.60
52-Week Range	27.00 - 41.75
Beta	0.43
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 10, 2026

About Mycenax Biotech

Mycenax Biotech Inc. provides biopharmaceutical services and solutions for drug development and production in Taiwan. The company’s services include program evaluation/confirmation, cell line development and construction, process development technology platforms, drug characterization analysis, establishment of testing methods, and PIC/S GMP drug production. It offers CDMO services, including integrated biologics development services, specialized modalities, manufacturing, and quality services. It also offers bispecific antibody production, and...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2001
• Employees: 387
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 4726

Financial Performance

In 2025, Mycenax Biotech's revenue was 740.24 million, an increase of 8.23% compared to the previous year's 683.92 million. Losses were -448.63 million, -3.96% less than in 2024.